塞利尼索在复发难治性多发性骨髓瘤中的研究进展

Research progress of selinexor in patients with relapsed and refractory multiple myeloma

多发性骨髓瘤(MM)为单克隆浆细胞恶性增殖性疾病,是血液系统发病率居第2位的肿瘤,随时间推移多数病人最终会发展为复发难治性多发性骨髓瘤(RRMM)。塞利尼索作为一种口服选择性核输出蛋白抑制剂,通过诱导恶性肿瘤细胞的凋亡而发挥抗肿瘤作用,于2019年7月3日被美国食品药品管理局(FDA)批准与地塞米松联合用于治疗RRMM。现对塞利尼索的作用机制、近年来的研究进展以及药物相关不良反应加以综述。

Multiple myeloma is a malignant proliferative disease of monoclonal plasma cells,and it is the second most common tumor in the blood system.In recent years,due to the application of various new drugs,new treatment methods and the development of autologous hematopoietic stem cell transplantation,the treatment effect in patients with multiple myeloma has been significantly improved.However,the disease remains incurable and most patients eventually develop relapsed and refractory multiple myeloma over time.Selinexor,an oral selective inhibitor of nuclear export proteasome that exerts anti-tumor effect by inducing apoptosis of malignant tumor cells,was approved by FDA on July 3,2019 in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma patients.This paper reviews the mechanism of action of Selinexor,recent research progress and drug-related adverse reactions.